Oncobiomed is a Chilean biotechnology company oriented towards commercializing, licensing and transferring the technology developed by a group of scientists from the University of Chile that research in the area of cancer therapy based on immunological approaches.

SERVICES

	Biological vaccines against malignant melanoma: TAPcells®
	Clinical research and cellular biotechnology in tumor immunology.
	Development of tumoral markers for diagnostic proceedures and/or adjuvant treatments of high-risk cancer patients.

RESEARCH

Oncobiomed specializes in the research and development of new technologies related to the development of biological vaccines for cancer immunotherapy. It applies the scientific research groups of investigators from the University of Chile and participates in research projects (FONDEF) in the area of cancer immunotherapy.

PAPERS

	2011: Clinical Cancer Research Heat-Shock Induction of Tumor-Derived Danger Signals Mediate Rapid Monocyte Differentiation into Clinically Effective Dendritic Cells
	2009: Journal of Clinical Oncology Prolonged Survival of Dendritic Cells-Vaccinated Melanoma Patients Correlates with Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor ß -expressing T Cells.
	Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape
	Melanocortin 1 Receptor Is Expressed by Uveal Malignant Melanoma and Can Be Considered a New Target for Diagnosis and Immunotherapy
	Clinical and Experimental Immunology 2005.pdf
	Immunobiology 2006.pdf